The polyprotein encoded by hepatitis C virus (HCV) genomic RNA is processed into functional polypeptides by both host-and virus-encoded proteases. The HCV-encoded NS3 protease and its cofactor peptide NS4A form a noncovalent complex, which participates in processing the viral polyprotein. This proteolytic activity is believed to be essential for virus proliferation and thus the NS3 protease is a prime target for developing anti-HCV pharmacological agents. Recent X-ray crystallography structural studies have revealed the nature of this non-covalent complex between NS3 protease and the 'active' central segment of NS4A, providing the opportunity to design a single-chain polypeptide. To this end, the DNA sequence encoding for the NS4A peptide (residues 21-34) was genetically fused via a short linker, capable of making a β-turn, to the Nterminus of the NS3 protease domain. This engineered single-chain NS3-protease (scNS3) is fully active with kinetic parameters virtually identical with those of the NS3/ NS4A non-covalent complex. Moreover, the scNS3 protease can be displayed on filamentous phage and affinity selected using an immobilized specific inhibitor. The scNS3 expressed as a soluble protein and in a phage-display format facilitates enzyme engineering for further structural studies and in vitro selection of potential drug-resistant mutants. These are important steps towards developing effective anti-protease compounds.
Introduction
The extent of hepatitis C virus (HCV) infection is estimated at about 100 million people world-wide (Alter, 1997) . HCV infection results in cirrhosis, hepatocellular carcinoma and chronic liver failure (Chien et al., 1992) , but as yet no effective treatments are available. The HCV virion contains a positivestranded RNA genome of 9.5 kb with a single open reading frame encoding for a large polyprotein (Choo et al., 1989) . During replication, the final steps of polyprotein processing are performed by a viral protease located in the N-terminal region of the NS3 protein (Tomei et al., 1993; Grakoui et al., 1993) . Proteolytic cleavage of the polyprotein is presumably essential to the viral replication process, hence the protease activity of the multifunctional 70 kDa NS3 protein is a particularly important target for pharmacological intervention. An interesting feature is that the NS3 protease requires an accessory viral protein, NS4A, for optimal cleavage activity. This is a small 6 kDa protein that appears to function also as a membrane anchorage of replication complexes (Tanji et al., 1995) . Its contribution to NS3 protease activity can be readily mimicked by a short synthetic peptide encompassing residues 21-34 of NS4A . The crystal structure of the NS3 protease domain (residue 1-181) complexed with a synthetic NS4A cofactor was determined (Kim et al., 1996; Yan et al., 1998) and it was found that NS4A (residues 21-34) is an integral component of the protease structure. In contrast to the six-stranded β-barrel N-terminus of the NS3 apoprotein (Love et al., 1996) , the NS3/NS4A heterodimer contains eight β-strands, including one provided by the NS4A peptide ( Figure 1A ). By virtue of this architecture, NS4A affects the enzyme conformation, its ability to bind substrates and plays a role in inducing structural changes at the enzyme active site (Landro et al., 1997; Yan et al., 1998) . We reasoned that by designing a catalytically active single-chain polypeptide, we would achieve substantial practical advantages: the enzyme would become more suitable for biochemical manipulation, possibly improving high-throughput screening assay formats, and, by reducing the number of variables, the design of co-crystallization experiments with enzyme inhibitors would become more straightforward. In addition, given the lack of a cell-based replication system and the expectation that the emergence of drug-resistant viruses will unquestionably be a major obstacle to developing effective HCV protease inhibitors, the scNS3 format would allow a phage-display system to be devised.
Filamentous bacteriophages have been used to display peptides and proteins on their viral surfaces, including several enzymes shown to be properly folded and active (reviewed by Smith and Petrenko, 1997) . Proteases such as trypsin (Corey et al., 1993) and subtilisin (Soumillion et al., 1994a) have also been displayed on phage. Different approaches have been established to select phage enzymes, based on interactions with inhibitors, substrates and transition state analogues and on the formation of covalent bonds (Soumillion et al., 1994a,b) .
Given the spatial proximity of the N-terminus of NS3 protease domain to the C-terminus of the complexed cofactor (corresponding to the central part) of NS4A, we engineered a small linker sequence that has the potential to adopt a β-turn conformation, to connect the two polypeptides chains covalently. The resulting single-chain NS3 protease (scNS3), derived from the J strain of HCV, is fully active with a k cat virtually identical with that of the NS3/NS4A non-covalent complex. In addition, the scNS3 is amenable to phage display by fusion to the C-terminal region of the pIII minor coat protein of bacteriophage f1 and can be affinity-selected using an immobilized inhibitor as a ligand.
The scNS3 constructs expressed either as a soluble protein or in a phage-display format could prove highly beneficial for the development of effective NS3 inhibitors; it would become feasible to use a combinatorial approach to engineer this enzyme for structural studies and to select drug-resistant variants in vitro. (B) Model of engineered (RGGP) β-turn (violet) that connects the C-terminus (R34) of NS4A (red) with the N-terminus (P2) residue of NS3 (green). The software InsightII (Biosym, San Diego, CA) was used to draw and display the molecule. The β-turn model was drawn by using the loop (residues 56-59) from protein G (PDB entry 1PGB) to connect the two β-strands and the side-chains mutated accordingly.
Materials and methods

Bacterial strains and phage stocks
The following Escherichia coli strains were used: TG1 for cloning, K91 for the generation of phage stocks and BL21-(DE3)pLysE (Novagen, Madison, WI) for expression of T7 promoter-driven NS3 protease constructs. M13K07 was used as helper phage. Phage manipulations and E.coli electroporation were carried out as described previously (Martin et al., 1994) . Recombinant DNA techniques and vectors Recombinant DNA techniques were carried out according to standard protocols or as recommended by suppliers. Nucleotide sequences were determined using Sequenase (United States Biochemical, Cleveland, OH) according to the supplier's recommendations. The pHEN-1 vector (Hoogenboom et al., 1991) and pT7 vector (Moffatt and Studier, 1987) have been described previously. The pHEC-FUS was constructed by PCR amplification (30 cycles at 94°C, 1 min; 58°C, 1 min; 72°C, 1.5 min) of the target sequence from pFUSIN (unpublished results), using the primers 5Ј-TTTTTTTGCTGCAGCGG-GGCGGCGGCTCAGTAGTAATCGTAGGCAGAA-3Ј and 5Ј-TTTTTTTGGATCCCCGCCGCCCCGCATGGTAGTTTC-CATAGACTCAACGGG-3Ј. The PCR product was digested with PstI and BamHI and ligated into pHEN-1 linearized with the same enzymes. The sequencing primer was 5Ј-AGCGGATAACAATTTCACACAGGA-3Ј. The pHECFUSper was used to express the histidine tagged scNS3 in E.coli periplasm and was obtained by digestion of pHEC-FUS vector with BamHI and EcoRI restriction enzymes (thus eliminating the carboxy-terminal region of pIII coat protein) and ligated with the following double-stranded oligonucleotide: 5Ј-GATCCAGGCCATCACCATCACCATCACGGCTAATA-AG-3Ј and 5Ј-AATTCTTATTAGCCG TGATGGTGATGGTG-ATGGCCTG-3Ј to introduce a polyhistidine tag plus a stop codon at the 3Ј end. The pT7scNS3 used for the expression of histidine tagged protein in the cytoplasm of E.coli was obtained by PCR amplification of the target sequence from the pHEC-FUS, using primers 5Ј-TTTTTTCATATGG-CGCCTATCGGCTCAGTAGTAATCGTAGGCAGAATCAT-CCT-3Ј and 5Ј-TTTTTTAAGCTTATTAGCCGTGATGG-TGATGGTGATGGCCTGGATCCCCGCCGCCCC-3Ј. The PCR conditions were 94°C, 30 s; 68°C, 30 s; 72°C, 45 s for 30 cycles. The PCR product was digested with NdeI and HindIII and ligated into pT7 linearized with the same enzymes. The sequence primer was 5Ј-TAATACGACTCACTAT-AGGCAGA-3Ј. All plasmid and DNA fragment purifications were carried out with a Wizard PCR Preps DNA Purification System and a Wizard Minipreps DNA Purification System (Promega, Madison, WI) or a Qiagen Plasmid Midi Kit (Qiagen, Chatsworth, CA). Ligations were made by the use of T4 DNA ligase (Boehringer Mannheim, Mannheim, Germany) at 14°C overnight. Restriction enzymes were purchased from New England Biolabs (Beverly, MA).
Construction, expression and purification of NS3
The construction, expression and purification of NS3-protease domain were described previously (Martin et al., 1997) . The protein was analyzed by SDS-PAGE/Western blot analysis, stained with an anti-NS3 polyclonal antibody (Tomei et al., 1993) and Ni-NTA conjugate reagent that recognizes the histidine tag (Qiagen, Santa Clara, CA). For scNS3, cultures in shaking flasks were grown in minimal medium (M9) supplemented with 5 g/l glucose, 1 mg/l (ϩ)-biotin, 2 mg/l thiamine, 1 g/l (NH 4 ) 2 SO 4 , 750 ml sterile water, 50 ml 10% casamino acids solution in water, 200 ml 5ϫ phosphate buffer (1ϫ PBS: 2.7 mM KCl, 1.5 mM KH 2 PO 4 , 810 mM Na 2 HPO 4 , 137 mM NaCl) and the appropriate antibiotic, at 22°C. When the culture reached OD 600 nm ϭ 0.8, production was induced by addition of 600 µM IPTG (isopropyl-β-D-thiogalactopyranoside) and the medium supplemented with 100 µM ZnCl 2 ; culture was then continued for 8 h and cells were collected by centrifugation. For the periplasmic extraction, the pellet was immediately resuspended in 1/10 of the original volume in 30 mM Tris, pH 7.4, 20% sucrose and left on ice for 30 min. Cells were centrifuged for 20 min at 2500 g and the supernatant was retained. The pellet was resuspended in 1/10 of the original volume of pre-cooled 5 mM MgSO 4 and incubated for another 30 min at 4°C. The solution was centrifuged and the supernatants were pooled, filtered and purified using IMAC (immobilized metal affinity chromatography) (Hochuli et al., 1987) and gel filtration by FPLC. The cytoplasmic protein was expressed from pT7 vector transformed in E.coli BL21 cells. Cultures were grown at 22°C in supplemented minimal medium in shaking flasks. Protein production was turned on when OD 600 nm reached 0.8, by addition of 600 µM IPTG, 100 µM ZnCl 2 and culture was continued for 8 h. Pellets were resuspended in 1/10 of the original volume of lysis buffer [20 mM NaH 2 PO 4, pH 6.3, 1 mM PMSF (phenylmethylsulfonyl fluoride), 10% glycerol, 5 mM β-mercaptoethanol, 1% 1-O-n-octyl-β-D-glucopyranoside, 500 mM NaCl, 0.02% NaN 3 ] and submitted to 30 cycles of microfluidization at 60 psi (Microfluidics, Newton, MA, USA). The lysate was centrifuged, filtered and purified as above. Fractions containing the purified scNS3 were pooled, concentrated with an Amicon ultrafiltration system with a YM10 membrane and stored at -70°C. Throughout the purification, the purity of the sample was monitored by SDS-PAGE with silver staining and by HPLC (high-performance liquid chromatography) using a reversed-phase Vydac C4 column (250ϫ4.6 mm i.d., 5 µm, 300 Å). The extinction coefficient of 18 200 l/mol.cm for scNS3 was calculated from its amino acid composition. A purified protein sample (Ͼ90%), from which concentration was determined by quantitative amino acid analysis, was used to calibrate a Bio-Rad protein assay which was routinely used during the purification procedure. LC-mass spectrometry (MS) was performed on a PerkinElmer API 100 instrument. N-Terminal analysis was carried out by Edman degradation of a protein sample extracted from a PVDF filter after SDS-PAGE and blotting was performed on an Applied Biosystems Model 470A gas-phase sequencer.
Gel filtration chromatography
Gel filtration experiments were performed on a Pharmacia FPLC system, on a 26/60 Superdex-75 preparative column equilibrated in 20 mM NaH 2 PO 4 (pH 6.3), 10% glycerol, 30 mM DTT (dithiothreitol), 0.1% 1-O-n-octyl-β-D-glucopyranoside, 500 mM NaCl, 0.02% NaN 3 ; analytical gel filtration was performed on a Pharmacia FPLC 10/30 Superdex-75 column in the same buffer with the appropriate NaCl concentration. The calibration run was carried out with a Pharmacia Biotech LMW gel filtration calibration kit, which includes the following markers: 200, 67, 43, 25 and 13.7 kDa.
Peptides
Our standard substrate (Steinkühler et al., 1996) was a 13 amino acid synthetic peptide derived from the cleavage site of the NS4A/NS4B junction (Ac-DEEMEC-ASHLPYK-NH 2 ). As proteinase cofactor, we used a 14mer peptide corresponding to the central hydrophobic core of the NS4A protein spanning residues 21-34 (NS4A: Ac-GSVVIVGRIILSGRKKK-NH 2 ), whereas in the case of scNS3 displayed on phage, HPLC analysis was carried out with the fluorogenic substrate Ac-DEMEEC-ASHLPYE(EDANS)-NH 2 , which includes an EDANS fluorophore [N-(aminoethyl)-5-naphthylamine-1-sulfonic acid]. Peptides were synthesized by a solid-phase method based on Fmoc chemistry. After cleavage and deprotection, the crude peptides were purified by HPLC to Ͼ98% purity. The identity of the peptides was checked by mass spectrometry. Concentration of stock solutions of peptides, prepared in DMSO (dimethyl sulfoxide) and kept at -70°C until used, was determined by quantitative amino acid analysis performed on HCl-hydrolyzed samples.
Protease assays
Assays were performed in 50 mM HEPES (N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid) (pH 7.5), 0.1% 1-O-noctyl-β-D-glucopyranoside, 15% glycerol, 30 mM DTT using 1259 20 nM scNS3 or NS3(1-181) and various concentrations of NaCl. As a control, the scNS3 was pre-incubated for 15 min with 60 µM of a 14mer peptide corresponding to the central domain of the protease cofactor NS4A. Reactions were started by adding 10 µM peptide substrate and, for phage-displayed scNS3, 20 µM substrate to 60 µl of assay mix. After 20 min at 25°C, the reactions were stopped by addition of 40 µl of a 1% TFA (trifluoroacetic acid) solution. A Beckman HPLC system equipped with an autosampler and a Shimadzu RF-551 fluorescence detector was used to analyze samples as described previously (Dimasi et al., 1997) . Peak detection was accomplished by monitoring both the absorbance at 220 nm and fluorescence (λ ex ϭ 260 nm, λ em ϭ 305 nm) and for the EDANS fluorophore (λ ex ϭ 355 nm, λ em ϭ 495 nm). Cleavage products were quantified by integrating the chromatograms with samples in which 100% conversion was achieved by 12 h of incubation. Initial rates of cleavage were determined on samples having Ͻ10% substrate conversion. MichaelisMenten constants K m and maximum velocities V max were obtained from non-linear least-squares fits of initial velocity data. The turnover number k cat was calculated from V max /E T , where E T is the total enzyme concentration. The k cat value was calculated from the equation
where [E] , the concentration of enzyme, was estimated using the molar extinction coefficient (18 200 l/mol.cm) and a Bio-Rad protein assay. IC 50 values were calculated as described previously (Dimasi et al., 1997) . All experiments were repeated at least three times.
In vitro translation of HCV NS5A/NS5B polyprotein substrate
The plasmid pCiteNS5A/B∆C51 expressing the NS5A/NS5B polyprotein cleavage site from residue 1965 to residue 3010 was described previously . The in vitro inhibition assay was carried out as described previously (Martin et al., 1997) .
Biotinylation of eglin-c and egl-EME mutant
The construction, expression and purification of eglin molecules used in this study were described previously (Martin et al., 1998) . Briefly, eglin-c is a 70 amino acid inhibitor of serine proteinases, isolated from Hirudo medicinalis (Seemüller et al., 1980) ; egl-EME is an eglin-c mutated in positions E 41 M 42 E 43 C 45 and is a selective inhibitor of NS3 proteinase (Martin et al., 1998) . In vitro biotinylation (Altin and Pagler, 1995) of egl-EME and eglin-c was performed using an EZLink Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL).
Preparation of phage-displayed scNS3 and affinity selection
Bacteriophage display of scNS3 was achieved from the phagemid construct pHEC-FUS using M13K07 as helper phage. The phages were concentrated with PEG (polyethyleneglycol), resuspended in 50 mM HEPES (pH 7.5), 30 mM DTT, 10% glycerol, 1% 1-O-n-octyl-β-D-glucopyranoside and dialyzed overnight at 4°C in the same buffer using 100 kDa cutoff membranes. For Western blot analyses 2.5ϫ10 9 T.U. (transducing units) phage particles per lane were subjected to 10% SDS-PAGE and blotted on to a PVDF (polyvinylidene fluoride) membrane. The membrane was subsequently incubated with anti-pIII antibody (MoBiTec, Göttingen, Germany) or with anti-NS3 antibody diluted 1:3000 in 0.1% PBS, 0.05% Tween 20. Subsequently it was incubated with anti rabbit-AP conjugate (Promega) diluted 1:5000 in 0.1% PBS, 0.05% Tween 20 and developed with NBT-BCIP (5-bromo-4-chloro- (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) was joined by a GG linker to P2 of NS3 (residues 2-181). In pHEC-FUS, the scNS3 gene was fused to the C-terminal domain (residues 198-406) of f1 minor coat protein (CTpIII). The PelB leader sequence is also shown. Relevant restriction enzyme sites are also indicated.
3-indolylphosphate-4-nitroblue tetrazolium chloride) solution (Boehringer Mannheim). Affinity selection was essentially the same as before (Martin et al., 1994) with the following modification: streptavidin-coated Dynabeads M-280 (Dynal) corresponding to 200 pmol of streptavidin were coated with a saturating amount (1.5 µM) of biotinylated egl-EME and eglinc according to the supplier's instructions. After 1 h of incubation at room temperature, the unbound biotinylated egl-EME and eglin-c were eliminated by five washes (200 µl, 3 min each) with PBS. The beads were then blocked for 1 h at room temperature with 3% (w/v) dialyzed bovine serum albumin in PBS and washed once again before use. The beads were then incubated overnight at 4°C with 2ϫ10 11 T.U. pHEC-FUS phage in selection buffer (SB: 50 mM HEPES, pH 7.5, 30 mM DTT, 10% glycerol, 25 mM NaCl, 1% 1-O-n-octyl-β-Dglucopyranoside). For binding competition experiments, beads were incubated in SB containing 1.5 µM of either unbiotinylated egl-EME or biotynilated eglin-c complexed with 2ϫ10 11 T.U. pHEC-FUS. Subsequently, the beads were washed 10 times at room temperature and resuspended in 300 µl of SB. The suspension was loaded on to 700 µl of a 30% sucrose cushion and the beads were collected by applying a magnetic field. This step was repeated a second time before elution of the bound phage with M NaCl in SB. The titer of eluted phage was determined by T.U. on ampicillin-or kanamicin-containing LB-agar plates for scNS3-phage and for M13K07 helper phage, respectively.
Results
The available structure of the truncated NS3/NS4A complex ( Figure 1A ) prompted us to design a single-chain polypeptide. Given the proximity of the N-terminus of NS3 protease domain and the C-terminus of NS4A, we reasoned that it was possible to build a small linker sequence that, by adopting a β-turn in a functional conformation, would connect the two polypeptide moieties ( Figure 1B) . We constructed the pT7scNS3 expression vector (Figure 2A ) by joining residue R34 of NS4A cofactor peptide to P2 of NS3 (residues 2-181) by virtue of a diGly sequence (RGGP). To ensure the proper redox potential required for protease activity, the construct was targeted to express the enzyme in the cytoplasmic compartment of Escherichia coli. In addition, to facilitate purification by IMAC (Hochuli et al., 1987) , a tag composed of GS(H) 6 was fused to the protease domain C-terminus. Western blot experiments (data not shown) revealed that about 40% of protein was recovered from the soluble fraction. The expression vector yielded 0.2-0.5 mg of purified (Ͼ90%) scNS3 per liter of culture. LC-MS and N-terminal amino acid sequencing confirmed both the identity and integrity of the purified protein.
To determine whether the purified scNS3 protein was enzymatically active, a peptide cleavage assay was used on a synthetic peptide substrate derived from the HCV NS4A/NS4B polyprotein cleavage site, whose sequence is Ac-DEMEEC-ASHLPYK-NH 2 (Steinkühler et al., 1996) . Steady-state kinetic studies were performed using substrate concentrations two to three orders of magnitude higher than the enzyme concentration, thus allowing Ͻ10% of the substrate to be cleaved by the protease (Tripton, 1993) . After 3 h of incubation at room temperature, we did not observe any loss of activity, indicating that the enzyme does not undergo degradation or destabilization in low salt buffer conditions (optimum for protease activity). The scNS3 protease was tested to verify if its enzymatic activity could be boosted by adding NS4A peptide cofactor in trans. The enzymatic activity of scNS3 proved to be insensitive to the addition of the NS4A cofactor in trans at a concentration of 60 µM (15-fold in excess over its K d ).
Next we checked the influence of ionic strength on the aggregation state of scNS3 in solution, by gel filtration chromatography. In solution, scNS3 exists as a monomer and as a trimer, with a molecular mass of 23 and 70 kDa, respectively (data not shown). Both species remained in solution after ultracentrifugation at 100 000 g or by filtration through a 0.2 µm filter. In the presence of 500 mM NaCl, the majority of the protein elutes as a 70 kDa species, whereas at 150 mM NaCl scNS3 is mostly a monomer of 23 kDa. Both forms are enzymatically active but the monomeric form is not activated by saturating amounts (60 µM) of NS4A cofactor, whereas the trimeric form is activated by a factor of 2-3 (Figure 3) . Furthermore, the trimeric form could be converted into the monomeric form by decreasing the ionic strength. Subsequently, we determined the kinetic parameters for the scNS3 protease activity on the NS4A/NS4B peptide substrate under different ionic strength conditions. The K m and k cat values are reported in Table I ; the k cat values are virtually the same under all conditions tested and well within the range of those of the non-covalent NS3/NS4A complex (1.5-1.8 min -1 ). As for the non-covalent NS3/NS4A complex, the K m of scNS3 is affected by ionic strength, increasing considerably in the presence of NaCl. Interestingly, the scNS3 is not further boosted by addition of NS4A in trans, indicating that the NS4A region packing is sufficiently stable under all conditions tested. To probe the enzyme active site further we tested if the scNS3 could be inhibited by egl-EME, a potent and selective macromolecule inhibitor of the NS3/NS4A complex, based on eglinc mutated in positions E 41 M 42 E 43 C 45 (Martin et al., 1998) . As reported in Figure 4 , egl-EME inhibited with virtually the same potency both enzyme forms with IC 50 of 0.62 and 0.58 µM for scNS3 and NS3/NS4A, respectively.
Because the redox potential of the periplasmic space is oxidizing and it is necessary to keep the NS3 protease in a reduced form to be active, it was crucial to verify if the scNS3 could be expressed in E.coli periplasmic space, fundamental for phage display. We therefore constructed pHEC-FUSper ( Figure 2B ) and, to make the redox potential of the periplasmic compartment a more favourable environment for expressing NS3 protease, we cultivated cells in medium supplemented with 100 mM reduced glutathione, as reported previously for expressing thiol-rich proteins (Missiakas and Raina, 1997) . We obtained yields in the range 0.1-0.5 mg of periplasmic protein per liter of culture. SDS-PAGE analysis confirmed Fig. 3 . Trans-activation by NS4A cofactor peptide. Percentage of protease activity is reported on the x-axis. Experiments carried out by HPLC assay are the average of at least three independent determinations. The enzyme concentration was 20 nM for NS3 protease domain and scNS3; scNS3-phage was 4ϫ10 9 T.U. The NS4A (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) cofactor was used at 60 µM; peptide substrates at 10 µM (Ac-DEEMEC-ASHLPYK-NH 2 ) for NS3 and scNS3 assay and 20 µM (Ac-DEMEEC-ASHLPYE(EDANS)-NH 2 ) for scNS3-phage assay. cyt indicates cytoplasmic preparation and per periplasmic. All assays were performed in the presence of 150 mM NaCl except for cyt scNS3*, which was carried out in the presence of 500 mM NaCl to test the trimeric form of the enzyme. The substrate sequence is Ac-DEEMEC-ASHLPYK-NH 2 . The values reported are the averages of at least three independent determinations. NS4A (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) cofactor concentration is 60 µM, the enzyme is 20 nM. Enzyme kinetics were determined in 50 mM HEPES (pH 7.5), 0.1% 1-O-noctyl-β-D-glucopyranoside, 15% glycerol, 30 mM DTT, as described in Materials and methods. a These parameters were determined in the same buffer containing 150 mM NaCl.
that the PelB leader peptide was no longer present (data not shown) and the processed protease was proved to be active both on the in vitro translated natural substrate corresponding to the NS5A/NS5B HCV cleavage site ( Figure 5 ) and on the synthetic substrate corresponding to the NS4A/NS4B (Figure 3 ). In the absence of 100 mM reduced glutathione in the medium, the purified protein retained less than 50% of its activity (data not shown). In addition, the periplasmic enzyme is not activated by NS4A cofactor (Figures 3 and 5) .
Having established the kinetic and biochemical properties of scNS3 and demonstrated that it is also active when expressed in the periplasmic space, we displayed it on phage by con- Fig. 4 . Determination of IC 50 for egl-EME inhibitor. Inhibition assays were performed in 50 mM HEPES buffer (pH 7.5), 0.1% 1-O-n-octyl-β-Dglucopyranoside, 15% glycerol, 30 mM DTT in the presence of Ac-DEEMEC-ASHLPYK-NH 2 synthetic substrate (10 µM). Percentage of residual enzyme activity (y-axis) was determined (mean of three determinations) as a function of inhibitor concentration (x-axis) and the IC 50 values derived. NS3 complexed with NS4A (21-34) cofactor peptide (diamonds) and scNS3 (circles). Both enzymes were tested at 20 nM and NS4A (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) at 60 µM. polyprotein substrate was transcribed in vitro using T7 polymerase and translated in reticulocyte lysate (Dimasi et al., 1997) . 100 pM of NS3 (lane 1), 100 pM of NS3 complexed with 60 µM of NS4A (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) peptide cofactor (lane 2), 100 pM of periplasmic scNS3 complexed with 60 µM NS4A (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) peptide cofactor (lane 3), 100 pM of periplasmic scNS3 (lane 4), 5 µl of in vitro translated NS5A/NS5B polyprotein substrate (lane 5). In this assay, the protease and NS4A (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) peptide cofactor were incubated for 20 min at room temperature; subsequently, the substrate was added and incubated for a further 30 min. Cleavage of the labelled precursor was assessed after separation by 10% SDS-PAGE and exposure on Phosphorimager (Molecular Dynamics).
Fig. 6.
In vitro activity and inhibition assay of scNS3-phage. 5ϫ10 9 T.U. of scNS3-phage were incubated with in vitro translated NS5A/NS5B HCV polyprotein precursor as described in Figure 5 , in the presence (60 µM) or absence of NS4A (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) peptide cofactor as indicated. Eglin molecules were tested at 1.5 µM (triplicate determinations) for their ability to inhibit the cleavage of in vitro translated NS5A/NS5B HCV polyprotein precursor by scNS3-phage (without NS4A cofactor), by monitoring the percentage of substrate conversion (y-axis), with respect to a control reaction where inhibitors were not included; 5 µl of in vitro translated NS5A/NS5B polyprotein (substrate) were included as a control. In both experiments the percentage conversion was determined by densitometric analysis of the radiolabelled product after separation by 10% SDS-PAGE and exposure on Phosphorimager (Molecular Dynamics). structing pHEC-FUS ( Figure 2B ), a fusion between scNS3 and the C-terminal domain of pIII protein. Bacteriophage particles displaying the scNS3 protease fusion were obtained from E.coli cells transformed with phagemid pHEC-FUS, cultivated in medium supplemented with 100 mM reduced glutathione and superinfected with M13K07 helper phage. Western blot analysis of phage proteins confirmed that the scNS3 is expressed on the phage surface (data not shown). The phage-borne scNS3 enzymatic activity was tested using a very sensitive assay which utilizes the in vitro translated natural substrate of HCV polyprotein (Tomei et al., 1993) . Phage preparations were subjected to dialysis using a 100 kDa cut-off membrane to ensure that the enzymatic activity detected is indeed phage-borne and not due to contaminant soluble enzyme. In this experiment the phagemid preparation with or without saturating amounts (60 µM) of NS4A peptide cofactor were incubated with radiolabelled NS5A/NS5B precursor pro- Fig. 7 . Affinity-selection of scNS3-phage. In all experiments 2ϫ10 11 T.U. of phage particles were used. The titer of affinity-selected phage was determined by counting the number of high salt-eluted (1 M NaCl) transducing units (T.U.) on ampicillin-containing LB-agar plates. The percentage of recovered phage is reported on the y-axis. scNS3-phage recovered from streptavidin-coated beads saturated with biotinylated egl-EME (a) and in the presence of an excess (1.5 µM) of non-biotinylated egl-EME (b); scNS3-phage recovered from a matrix made of biotinylated wild type eglin-c (c) or of streptavidin and nonbiotinylated egl-EME (d) or of streptavidin beads only (e); wild-type f1 virions incubated with complete matrix containing biotynilated egl-EME (f). Data are means of at least three independent experiments. The experimental scheme is shown as an inset and the legend is shown on the right.
tein. The phage-borne enzyme was proved to be fully active in the absence of NS4A peptide provided in trans (Figure 6 ).
Using the same assay we tested whether the activity of the scNS3-phage preparation could be inhibited by the engineered NS3 inhibitor egl-EME, described previously (Martin et al., 1998) . The results confirmed that this scNS3 was indeed blocked by this inhibitor with the same relative potency as the NS3/NS4A complex (Martin et al., 1998) . In addition, the activity of the phage-enzyme was confirmed in the HPLC assay (Figure 3 ) using the fluorescent synthetic substrate Ac-DEMEEC-ASHLPYE(EDANS)-NH 2 . The phage displaying scNS3 is also active on the natural substrate NS5A/NS5B (Figure 6 ). Taken together, these results show that the phageborne scNS3 is active, correctly folded and potentially amenable to affinity-selection experiments.
To test the latter, we investigated if virions could bind selectively to a specific solid support consisting of immobilized egl-EME inhibitor. Experiments were carried out by incubating the phage bearing the active enzyme with the solid phase-bound egl-EME. The N-terminus of this inhibitor was biotinylated and captured on streptavidin-coated magnetic beads. Notably, the biotinylated inhibitor has the same potency as the non-biotinylated inhibitor (data not shown). The binding of phage-inhibitor complexes to the solid phase (Figure 7a ) is specifically inhibited by preincubation of the phage enzyme with an excess (1.5 µM) of non-biotinylated egl-EME inhibitor (Figure 7b ). The selectivity of this binding reaction is further demonstrated as scNS3-phage does not bind to the solid phase consisting of immobilized biotinylated wild-type eglin c (Figure 7c ), which does not inhibit NS3/NS4A protease (Martin et al., 1998) . In addition, scNS3-phage does not bind either to the matrix devoid of biotinylated egl-EME inhibitor (Figure 7d ) or to streptavidin beads without egl-EME (Figure 7e ). Virions that do not bear scNS3 are unable to bind the complete matrix (Figure 7f ). In conclusion, the phage-displayed enzyme is fully active and affinity selectable by specifically designed ligands.
Discussion
The viral-encoded NS3 protease is considered one of the most important targets for developing HCV therapeutics. Hence compounds able to interfere with the protease activity of this enzyme are promising drug candidates. The NS4A polypeptide is required as a cofactor and the minimum sequence necessary to activate NS3 was identified in its central hydrophobic core from residue 21 to 34 . Crystal structures of the NS3/NS4A complex published recently (Kim et al., 1996; Yan et al., 1998) have shown that the synthetic 14mer peptide of NS4A is an integral component of the protease structure.
We reasoned, for a number of practical purposes, that it could be very advantageous to have a single polypeptide rather than a non-covalent complex. In addition, we wanted to develop a phage-display format to allow the selection of alternative and/or optimum substrates and also enzyme variants that may be resistant to inhibitors in vitro. We feel that these developments are crucial for drug discovery, given the present lack of an efficient in vitro HCV replication system in which to monitor the impact of potential inhibitors in inducing the emergence of drug-resistant protease mutants. Surrogate cellbased systems based on chimeric viruses such as sindbis (Filocamo et al., 1997) and polio (Hahm et al., 1996) , useful to test potential inhibitors, have been described. Phage display, however, offers an alternative strategy with some advantages, albeit with the limitations of a non-cellular system. Certainly, it remains to be verified whether the in vitro selection would be truly predictive of which mutations might arise in a clinical setting. In principle, to mimic more closely a clinical circumstance it should be possible to display on phage in a single-chain format a natural NS3 repertoire cloned from patients.
By using phage display, enzymes with altered specificities have been selected (reviewed by Smith and Petrenko, 1997) .
The engineered scNS3 protease was expressed on the surface of filamentous bacteriophage as a fusion to pIII coat protein and is catalytically active both on the NS5A/NS5B polyprotein substrate and on the synthetic substrate. Bacteriophage expressing the scNS3-pIII fusion could be selected using an immobilized inhibitor and specifically eluted, thus offering the opportunity to select drug-resistant enzymes in vitro. Ideally, if mechanism-based inhibitors such as a 'serine trap' were available, it would be possible to select for catalytic efficiency, as reported previously (Soumillion et al., 1994a,b) . Based on previous extensive literature (reviewed by Smith and Petrenko, 1997) , we believe that the degree of specificity achieved in the affinity-selection of scNS3-phage with the eglin inhibitor is a valid indicator of its potential for screening repertoires of scNS3 mutants with specific properties.
The linker sequence (RGGP) is capable of adopting a β-turn joining the two β-strands deriving from NS4A and the NS3 protease N-terminus. The purified protein exhibited protease activity with k cat very similar to that of the noncovalent complex and is not activated by NS4A cofactor peptide, indicating that the enzyme is correctly folded. The K m value for the NS4A/NS4B peptide substrate is the same as that of the NS3/NS4A complex, further supporting the view that the enzyme is virtually the same as the heterodimer. Notably, our kinetic data are in line with those previously published (Steinkühler et al., 1996; Landro et al., 1997; Urbani et al., 1997; Vishnuvardhan et al., 1997; Zhang et al., 1997) . The difference in accuracy of reported k cat values under different ionic strength conditions is due to the dramatic increase in the K m values of the substrate used in our study with increasing salt concentration. Since solubility of the substrate poses a limit to the maximum concentration that can be used in the assay, only a few experimental points above K m are accessible in the presence of high salt, whereas Ͼ90% substrate saturation can be attained under conditions of low ionic strength. This inevitably leads to different quality of k cat estimations.
Other authors have recently described single-chain constructs, albeit with substantial differences from the construct described here; namely they have different connectivities and make use of full-length NS4A protein. An E.coli expressed protein consisting of full-length NS4A fused to the C-terminus of NS3 protease domain was shown to be active on an NS5A/ NS5B substrate (Inoue et al., 1998) . Similarly, another protein consisting of full-length NS4A covalently linked through a polyglycine to the C-terminus of an NS3 protease domainmaltose-binding protein fusion was also described (Wilkinson et al., 1997) . This soluble protein was shown to be fully active on NS4A/NS4B and NS5A/NS5B substrates. However, neither study provides sufficient biochemical data to allow one unequivocally to conclude that activation by NS4A is an intra-or inter-molecular event.
Like the NS3/NS4A complex, the scNS3 can be inhibited by the engineered NS3 inhibitor egl-EME (Martin et al., 1998) . NaCl also inhibited the scNS3 protease activity as with the NS3/NS4A heterodimer and it inversely correlates with the trimeric state of the engineered sc-enzyme. In high ionic strength conditions, the enzyme forms a 70 kDa species which is partially activated by NS4A, whereas at NaCl concentrations below 150 mM, the enzyme is a fully active monomer, which is not further activated by addition of saturating amounts (60 µM) of NS4A peptide. In contrast, the trimeric form is activated by NS4A 2-3-fold, instead of the 10-15-fold for the apoprotein, suggesting that a portion of the N-terminus of this enzyme is available to bind the NS4A peptide provided in trans. In contrast to the truncated protease, a recent study performed on the full-length, non-covalent (70 kDa) NS3/ NS4A native complex demonstrated that by using the NS5A/ NS5B substrate the activity of the NS3 protease is optimum at 300 mM NaCl concentration; under these conditions, the monomeric fully active heterodimer enzyme complex is stabilized (Sali et al., 1998) .
The scNS3 construct also offers potential benefits for structural studies such as X-ray crystallography and NMR. To take full advantage of the single-chain format, however, it will be necessary to improve the yield of recombinant protein. Work is in progress to address this issue.
